154 completed, 59 terminated, 21 unknown, 14 active not recruiting. 271 Phase 2, 50 Phase 1, 3 Phase 3.
Follow Velcade: new trials by email Literature Review of Velcade trials Research Report on Velcade
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma Isatuximab, Iberdomide, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 88 | 2026-09-03 | 2026-09-03 |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) Belantamab mafodotin, Dexamethasone, Pomalidomide - Multiple Myeloma | Phase 2 | Recruiting | GlaxoSmithKline | 200 | 2026-04-15 | 2026-08-25 |
| Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure Cyclophosphamide, Bortezomib (VELCADE), Dexamethasone - Myeloma Multiple | Phase 2 | Recruiting | Eastern Cooperative Oncology Group | 74 | 2026-03-05 | 2026-11-16 |
| Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients Iberdomide, Bortezomib, Dexamethasone - Multiple Myeloma | Phase 2 | Recruiting | Canadian Myeloma Research Group | 75 | 2024-12-12 | 2026-08-31 |
| Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Multiple Myeloma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 58 | 2024-07-23 | 2026-09-25 |
| Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis Bortezomib, Pomalidomide, Dexamethasone - Systemic Amyloidosis | Phase 2 | Recruiting | Jin Lu, MD | 40 | 2024-05-06 | 2024-12-30 |
| Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS Daratumumab, Bortezomib, Lenalidomide - Multiple Myeloma | Phase 2 | Unknown | Stichting European Myeloma Network | 200 | 2023-11-23 | 2024-04-23 |
| Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma Daratumumab, Carfilzomib, Lenalidomide - Multiple Myeloma, Primary Plasma Cell Leukemia | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 54 | 2023-10-20 | 2025-04-16 |
| CURATE.AI Optimized Modulation for Multiple Myeloma Bortezomib, Cyclophosphamide, Dexamethasone - Multiple Myeloma | Phase 2 / Phase 3 | Unknown | National University Hospital, Singapore | 20 | 2023-09-10 | 2023-09-06 |
| Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial Bortezomib, Dexamethasone, Pelareorep - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 / Phase 2 | Active not recruiting | University of Southern California | 10 | 2022-10-07 | 2026-05-13 |
| Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study Bortezomib, Daratumumab, Dexamethasone - Plasma Cell Myeloma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 49 | 2022-08-11 | 2026-10-16 |
| Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma Selinexor, Bortezomib, Lenalidomide - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Xia Zhongjun | 42 | 2022-07-25 | 2024-06-17 |
| Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency Bortezomib, Isatuximab, Cyclophosphamide - Multiple Myeloma | Phase 2 | Recruiting | Medical College of Wisconsin | 41 | 2021-11-02 | 2026-01-28 |
| Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients Selinexor 20 MG Oral Tablet, Bortezomib Injection, Lenalidomide capsule - Multiple Myeloma | Phase 2 | Active not recruiting | Ida Bruun Kristensen | 50 | 2021-08-18 | 2026-10-16 |
| Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma Acalabrutinib, Bortezomib, Cyclophosphamide - Mantle Cell Lymphoma | Phase 2 | Active not recruiting | Academic and Community Cancer Research United | 41 | 2021-08-03 | 2026-08-25 |
| DARA RVD For High Risk SMM Daratumumab, Bortezomib, Lenalidomide - High-risk Smoldering Multiple Myeloma, Multiple Myeloma | Phase 2 | Active not recruiting | Omar Nadeem, MD | 61 | 2021-03-08 | 2026-07-02 |
| VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma bortezomib, Lenalidomide, Dexamethasone - Myeloma, Newly Diagnosed | Phase 2 | Unknown | Sun Yat-sen University | 50 | 2020-09-25 | 2023-06-18 |
| A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. Selinexor, Dexamethasone, Bortezomib - Multiple Myeloma, Refractory | Phase 2 | Recruiting | Karyopharm Therapeutics Inc | 127 | 2020-07-01 | 2026-10-29 |
| A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment Bortezomib Injection - Myeloma, Myeloma Multiple | Phase 2 | Terminated | AHS Cancer Control Alberta | 39 | 2020-05-29 | 2026-10-28 |
Showing 20 of 271. Sign in to see all of them.
Multiple Myeloma (122) · Lymphoma, Mantle-Cell (24) · Recurrence (19) · Lymphoma (17) · Lymphoma, Non-Hodgkin (16) · Lymphoma, Follicular (15) · Neoplasms, Plasma Cell (14) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (12) · Leukemia, Myeloid, Acute (10) · Lymphoma, Large B-Cell, Diffuse (10) · Waldenstrom Macroglobulinemia (9) · Carcinoma, Non-Small-Cell Lung (8) · Leukemia (7) · Immunoglobulin Light-chain Amyloidosis (6) · Amyloidosis (5)
National Cancer Institute (NCI) (41) · M.D. Anderson Cancer Center (13) · Dana-Farber Cancer Institute (11) · Millennium Pharmaceuticals, Inc. (8) · University of Arkansas (8) · Mayo Clinic (7) · Duke University (5) · Emory University (4) · Fred Hutchinson Cancer Center (4) · H. Lee Moffitt Cancer Center and Research Institute (4) · Northwestern University (4) · PETHEMA Foundation (4) · SCRI Development Innovations, LLC (4) · Hackensack Meridian Health (3) · Korean Multiple Myeloma Working Party (3)
United States (195) · Germany (14) · Canada (13) · France (12) · Greece (12) · Spain (12) · Italy (11) · China (10) · South Korea (10) · United Kingdom (8) · Australia (7) · Netherlands (7) · Czechia (6) · Belgium (5) · Brazil (4)
Irene Ghobrial, MD (4) · Maurizio Zangari, MD (3) · E. Steve Woodle, MD (2) · Jae Hoon Lee, M.D. (2) · James R Berenson, MD (2) · Joanne Filicko-O'Hara, MD (2) · John Koreth, MBBS, DPhil (2) · Leona Holmberg (2) · Melissa Alsina, MD (2) · Paul Richardson, MD (2) · Shaji Kumar, M.D. (2) · Vaishali Sanchorawala, MD (2) · Ajay Nooka, MD, MPH (1)
PMID 33357481, PMID 29567784, PMID 36184192, PMID 40501401, PMID 15613697, PMID 18327587, PMID 19498019, PMID 19528374, PMID 19692142, PMID 19860608, PMID 19884643, PMID 20012045, PMID 20142586, PMID 20582937, PMID 20661232, PMID 20956803, PMID 21239695, PMID 21241279, PMID 21345726, PMID 21562045, PMID 21596852, PMID 21911830, PMID 21990396, PMID 22535574, PMID 22653976, PMID 22674807, PMID 22689675, PMID 22733020, PMID 22773122, PMID 23305732, PMID 23603914, PMID 23940282, PMID 24048792, PMID 24458437, PMID 24526575, PMID 24890858, PMID 25039282, PMID 25202139, PMID 25294016, PMID 25572917, PMID 25777345, PMID 25813205, PMID 25824111, PMID 25833390, PMID 25911554, PMID 26055298, PMID 26139427, PMID 26232170, PMID 26248505, PMID 26285768
U10CA021115 (7), U10CA031946 (7), N01CM62205 (4), U10CA032102 (4), U10CA180821 (4), N01CM62204 (3), P30CA015704 (3), U10CA098543 (3), 2005 (2), 2008 (2), 2015 (2), 2016 (2), N01CM17003 (2), N01CM62203 (2), N01CM62208 (2)